Your browser is no longer supported. Please, upgrade your browser.
Settings
IMUX Immunic, Inc. daily Stock Chart
IMUX [NASD]
Immunic, Inc.
Index- P/E- EPS (ttm)-34.26 Insider Own0.30% Shs Outstand8.34M Perf Week9.15%
Market Cap92.49M Forward P/E- EPS next Y-2.90 Insider Trans- Shs Float- Perf Month-28.08%
Income-36.60M PEG- EPS next Q-0.59 Inst Own1.70% Short Float- Perf Quarter32.66%
Sales- P/S- EPS this Y25.10% Inst Trans6.78% Short Ratio0.50 Perf Half Y-5.38%
Book/sh8.28 P/B1.34 EPS next Y- ROA-182.30% Target Price50.00 Perf Year-95.45%
Cash/sh1.15 P/C9.63 EPS next 5Y15.50% ROE-235.30% 52W Range6.04 - 390.00 Perf YTD48.82%
Dividend- P/FCF- EPS past 5Y12.00% ROI- 52W High-97.16% Beta4.02
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low83.61% ATR1.67
Employees10 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)50.12 Volatility13.32% 10.38%
OptionableNo Debt/Eq0.00 EPS Q/Q36.10% Profit Margin- Rel Volume0.51 Prev Close9.15
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume241.16K Price11.09
Recom1.00 SMA20-5.54% SMA50-17.12% SMA200-78.58% Volume123,264 Change21.20%
May-09-19 06:30AM  Immunic, Inc. to Participate in Upcoming May Conferences PR Newswire
Apr-29-19 06:30AM  Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer PR Newswire
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.